Amgen Inc. (NASDAQ:AMGN) Shares Sold by Hunter Associates Investment Management LLC

Hunter Associates Investment Management LLC lowered its position in shares of Amgen Inc. (NASDAQ:AMGNFree Report) by 1.6% in the fourth quarter, according to the company in its most recent filing with the SEC. The firm owned 55,240 shares of the medical research company’s stock after selling 924 shares during the quarter. Amgen comprises about 2.9% of Hunter Associates Investment Management LLC’s portfolio, making the stock its 4th largest position. Hunter Associates Investment Management LLC’s holdings in Amgen were worth $15,912,000 at the end of the most recent reporting period.

A number of other institutional investors have also modified their holdings of the stock. Vanguard Group Inc. raised its stake in shares of Amgen by 0.3% during the 3rd quarter. Vanguard Group Inc. now owns 49,035,981 shares of the medical research company’s stock valued at $13,178,910,000 after buying an additional 165,636 shares during the last quarter. Morgan Stanley raised its stake in shares of Amgen by 12.9% during the 4th quarter. Morgan Stanley now owns 13,301,365 shares of the medical research company’s stock valued at $3,493,471,000 after buying an additional 1,523,665 shares during the last quarter. Charles Schwab Investment Management Inc. raised its stake in shares of Amgen by 1.1% during the 1st quarter. Charles Schwab Investment Management Inc. now owns 8,819,690 shares of the medical research company’s stock valued at $2,132,778,000 after buying an additional 94,565 shares during the last quarter. Moneta Group Investment Advisors LLC raised its stake in shares of Amgen by 83,875.6% during the 4th quarter. Moneta Group Investment Advisors LLC now owns 7,541,011 shares of the medical research company’s stock valued at $1,980,571,000 after buying an additional 7,532,031 shares during the last quarter. Finally, Northern Trust Corp raised its stake in shares of Amgen by 3.8% during the 3rd quarter. Northern Trust Corp now owns 6,977,625 shares of the medical research company’s stock valued at $1,875,306,000 after buying an additional 255,463 shares during the last quarter. Hedge funds and other institutional investors own 76.50% of the company’s stock.

Analyst Upgrades and Downgrades

Several equities analysts recently weighed in on the company. Leerink Partnrs lowered Amgen from an “outperform” rating to a “market perform” rating in a research note on Wednesday, February 7th. Oppenheimer restated an “outperform” rating and issued a $350.00 price target on shares of Amgen in a research note on Thursday, February 1st. Morgan Stanley cut their price target on Amgen from $281.00 to $278.00 and set an “equal weight” rating for the company in a research note on Wednesday, February 7th. StockNews.com lowered Amgen from a “buy” rating to a “hold” rating in a research note on Thursday, March 28th. Finally, Truist Financial restated a “buy” rating and issued a $320.00 price target on shares of Amgen in a research note on Friday, April 12th. Ten investment analysts have rated the stock with a hold rating and ten have assigned a buy rating to the stock. Based on data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $296.95.

View Our Latest Analysis on Amgen

Amgen Price Performance

NASDAQ:AMGN opened at $268.93 on Friday. Amgen Inc. has a 12 month low of $211.71 and a 12 month high of $329.72. The stock has a 50 day moving average of $276.90 and a two-hundred day moving average of $281.40. The company has a current ratio of 1.65, a quick ratio of 1.13 and a debt-to-equity ratio of 10.14. The firm has a market cap of $144.25 billion, a P/E ratio of 21.53, a price-to-earnings-growth ratio of 2.50 and a beta of 0.58.

Amgen (NASDAQ:AMGNGet Free Report) last issued its earnings results on Tuesday, February 6th. The medical research company reported $4.71 earnings per share for the quarter, topping the consensus estimate of $4.66 by $0.05. The business had revenue of $8.20 billion for the quarter, compared to analysts’ expectations of $8.13 billion. Amgen had a return on equity of 154.27% and a net margin of 23.83%. The business’s revenue for the quarter was up 19.8% compared to the same quarter last year. During the same period in the previous year, the firm posted $4.09 EPS. On average, analysts expect that Amgen Inc. will post 19.45 earnings per share for the current fiscal year.

Amgen Dividend Announcement

The business also recently announced a quarterly dividend, which will be paid on Friday, June 7th. Stockholders of record on Friday, May 17th will be issued a dividend of $2.25 per share. This represents a $9.00 annualized dividend and a dividend yield of 3.35%. The ex-dividend date is Thursday, May 16th. Amgen’s dividend payout ratio is currently 72.06%.

About Amgen

(Free Report)

Amgen Inc discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for men and women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout.

See Also

Institutional Ownership by Quarter for Amgen (NASDAQ:AMGN)

Receive News & Ratings for Amgen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amgen and related companies with MarketBeat.com's FREE daily email newsletter.